BridgeBio Oncology Therapeutics, Inc.
BBOT
$6.76
-$2.11-23.76%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -108.13% | -90.50% | -80.47% | -- | -- |
| Total Depreciation and Amortization | 121.83% | 253.33% | 193.27% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,044.77% | 465.16% | 280.35% | -- | -- |
| Change in Net Operating Assets | 64.25% | -40.62% | -58.75% | -- | -- |
| Cash from Operations | -87.00% | -98.01% | -106.98% | -- | -- |
| Capital Expenditure | 31.40% | -137.56% | -1,136.73% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -453.83% | -111.42% | 161.37% | -- | -- |
| Cash from Investing | -457.10% | -111.47% | 160.84% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 719,044.23% | 97,784.29% | 33,428.01% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | -88.85% | -89.17% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -139.05% | -2,879.95% | -- | -- | -- |
| Cash from Financing | 1,862.92% | 92.78% | 85.86% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 358.90% | 2.00% | 1,015.53% | -- | -- |